SCHEMBL16214712

SCHEMBL16214712

CCOC(=O)[C@]1(C)CCCC[C@H]1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 8/20 0.49
PTPN2 P17706 2/20 0.41
PTPN1 P18031 2/20 0.41
CDC25B P30305 2/20 0.41
GLI1 P08151 1/20 0.37
CYP3A4 P08684 2/20 0.36
ABCB11 O95342 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CYP2D6 P10635 1/20 0.36
CHRM1 P11229 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
CHRM3 P20309 1/20 0.36
DRD1 P21728 1/20 0.36
HRH2 P25021 1/20 0.36
HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1066368 1.00 F10 (0.49) F10PTPN2PTPN1CDC25BGLI1
SCHEMBL16391282 1.00 F10 (0.49) F10PTPN2PTPN1CDC25BGLI1
SCHEMBL27634524 0.95 F10 (0.50) F10PTPN2PTPN1CDC25BGLI1
SCHEMBL20221633 0.95 F10 (0.50) F10PTPN2PTPN1CDC25BGLI1
SCHEMBL16391387 0.95 F10 (0.50) F10PTPN2PTPN1CDC25BGLI1
SCHEMBL16409183 0.84 CYP3A4 (0.39) F10CYP3A4ABCB11LMNACYP1A2
SCHEMBL10177221 0.81 F10 (0.42) F10PTPN2PTPN1CDC25BGLI1
SCHEMBL10389179 0.81 KDM4E (0.40) F10CYP3A4ABCB11LMNACYP1A2
SCHEMBL18629017 0.80 MEN1 (0.46) GLI1CYP3A4MEN1MAPK1KMT2A
SCHEMBL21950906 0.80 F10 (0.41) F10PTPN2PTPN1CDC25BCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150126511-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2015-05-07 US disclosed
US-8877975-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2014-11-04 US disclosed
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2010-07-29 US disclosed
US-20070203111-A1 Cycloalkylamines as monoamine reuptake inhibitors SEPRACOR INC. (US) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150126511-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 F10 3133/4885PTPN2 2933/4885PTPN1 2981/4885
US-20070203111-A1 Cycloalkylamines as monoamine reuptake inhibitors SLC18A2, SLC6A2, SLC18A3 F10 3133/4885PTPN2 2933/4885PTPN1 2981/4885
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 F10 3133/4885PTPN2 2933/4885PTPN1 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.